[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2015000715A1 - Anti-androgenos para el tratamiento de cáncer prostatico no metastasico y resistente de castracion - Google Patents

Anti-androgenos para el tratamiento de cáncer prostatico no metastasico y resistente de castracion

Info

Publication number
CL2015000715A1
CL2015000715A1 CL2015000715A CL2015000715A CL2015000715A1 CL 2015000715 A1 CL2015000715 A1 CL 2015000715A1 CL 2015000715 A CL2015000715 A CL 2015000715A CL 2015000715 A CL2015000715 A CL 2015000715A CL 2015000715 A1 CL2015000715 A1 CL 2015000715A1
Authority
CL
Chile
Prior art keywords
castration
prostate cancer
androgens
metastatic
treatment
Prior art date
Application number
CL2015000715A
Other languages
English (en)
Inventor
Isan Chen
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49293921&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000715(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of CL2015000715A1 publication Critical patent/CL2015000715A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

USO DE UN ANTIANDROGENO PARA TRATAR UN CANCER DE PROSTATA RESISTENTE A LA CASTRACION NO METASTASICO EN UN VARON.
CL2015000715A 2012-09-26 2015-03-20 Anti-androgenos para el tratamiento de cáncer prostatico no metastasico y resistente de castracion CL2015000715A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261705900P 2012-09-26 2012-09-26

Publications (1)

Publication Number Publication Date
CL2015000715A1 true CL2015000715A1 (es) 2015-12-11

Family

ID=49293921

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000715A CL2015000715A1 (es) 2012-09-26 2015-03-20 Anti-androgenos para el tratamiento de cáncer prostatico no metastasico y resistente de castracion

Country Status (35)

Country Link
US (7) US9884054B2 (es)
EP (3) EP2900224A1 (es)
JP (4) JP6351597B2 (es)
KR (3) KR20220025231A (es)
CN (4) CN109999036A (es)
AU (4) AU2013323861C1 (es)
BR (1) BR112015006705A8 (es)
CA (1) CA2885415C (es)
CL (1) CL2015000715A1 (es)
CR (1) CR20150140A (es)
CY (1) CY1123716T1 (es)
DK (1) DK3305285T3 (es)
EA (3) EA030128B1 (es)
EC (1) ECSP15011764A (es)
ES (1) ES2836424T3 (es)
GT (1) GT201500071A (es)
HK (2) HK1212221A1 (es)
HR (1) HRP20201721T1 (es)
HU (1) HUE051211T2 (es)
IL (3) IL312316A (es)
IN (1) IN2015DN02387A (es)
LT (1) LT3305285T (es)
MX (2) MX371020B (es)
MY (1) MY180834A (es)
NI (1) NI201500042A (es)
NZ (3) NZ705815A (es)
PE (1) PE20150765A1 (es)
PH (3) PH12015500615A1 (es)
PT (1) PT3305285T (es)
RS (1) RS60976B1 (es)
SG (3) SG11201501870RA (es)
SI (1) SI3305285T1 (es)
UA (2) UA117663C2 (es)
WO (1) WO2014052237A1 (es)
ZA (1) ZA201808499B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103202A2 (en) 2010-02-16 2011-08-25 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
KR20140103335A (ko) 2011-12-16 2014-08-26 올레마 파마슈티컬스 인코포레이티드 신규한 벤조피란 화합물, 조성물 및 이의 용도
HUE051211T2 (hu) 2012-09-26 2021-03-01 Aragon Pharmaceuticals Inc Antiandrogének nem áttétes, kasztrációrezisztens prosztatarák kezelésére
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
HUE051888T2 (hu) * 2014-12-05 2021-03-29 Aragon Pharmaceuticals Inc Rákellenes készítmények
AU2015358497B2 (en) 2014-12-05 2021-04-29 Aragon Pharmaceuticals, Inc. Anticancer compositions
KR101718226B1 (ko) 2015-08-05 2017-03-20 울산대학교 산학협력단 사쿠라소사포닌 화합물을 유효성분으로 포함하는 안드로겐 수용체 관련 질환의 예방 또는 치료용 조성물
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP4438126A2 (en) * 2017-10-16 2024-10-02 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
AU2020215176A1 (en) * 2019-01-30 2021-08-05 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
US11723898B2 (en) * 2019-11-04 2023-08-15 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE550650A (es) 1955-08-30
JPS4916937B1 (es) 1970-01-21 1974-04-25
US3823240A (en) 1970-10-06 1974-07-09 Rhone Poulenc Sa Fungicidal hydantoin derivatives
GB1472467A (en) 1974-04-19 1977-05-04 Wyeth John & Brother Ltd Thiohydantoins
FR2329276A1 (fr) 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
DE2614831A1 (de) 1976-04-06 1977-10-20 Bayer Ag 1,3,4-thiadiazolylderivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
IL55774A (en) 1977-10-28 1982-04-30 Sparamedica Ag Pharmaceutical compositions containing urea derivatives,certain such novel derivatives and their manufacture
MC1220A1 (fr) 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
JPS5492962A (en) 1977-12-01 1979-07-23 Wellcome Found Thiohydantoin compound
EP0004723A1 (en) 1978-03-30 1979-10-17 Beecham Group Plc Deoxyhydantoins, processes for their preparation and pharmaceutical compositions containing them
FR2449448B1 (fr) 1979-02-20 1983-05-27 Inst Nat Radio Elements Composition pharmaceutique comprenant un derive de phenylhydantoine, derives mis en oeuvre et leur preparation
FI801184A (fi) 1979-04-24 1980-10-25 Hoffmann La Roche Foerfarande foer framstaellning av imidazolidinderivat
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
JPS57197268A (en) 1981-05-29 1982-12-03 Sumitomo Chem Co Ltd Substituted phenylhydantoin derivative, its preparation, and herbicide containing the same as active ingredient
EP0091596B1 (de) 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Neue Hydantoine, ihre Herstellung und Verwendung
US4473393A (en) 1982-08-06 1984-09-25 Buffalo Color Corporation Pesticidal thiohydantoin compositions
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
JPS59210083A (ja) 1983-05-13 1984-11-28 Otsuka Chem Co Ltd １，３，４−チアジアゾ−ル−５−オン誘導体、その製造法及び該誘導体を有効成分とする除草剤
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS6092285A (ja) 1983-10-26 1985-05-23 Shionogi & Co Ltd イソオキサゾ−ル系環状尿素類
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPS60239737A (ja) 1984-05-14 1985-11-28 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
JPH0219363Y2 (es) 1985-07-31 1990-05-29
EP0230654B1 (en) 1985-12-28 1992-03-18 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
DE3604042A1 (de) 1986-02-08 1987-08-13 Hoechst Ag Imidazolidin(thi)on-derivate, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
JPS649978A (en) 1987-07-02 1989-01-13 Shionogi & Co Perfluoroalkylisoxazole derivative
US4859228A (en) 1987-07-16 1989-08-22 Ici Americas Inc Novel 5-aminomethylene-2,4-imidazolidinediones and 5-aminomethylene-2-thionoimidazolidine-4-ones
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
FR2619381B1 (fr) 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
CA1331757C (en) 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
US5614620A (en) 1988-03-30 1997-03-25 Arch Development Corporation DNA binding proteins including androgen receptor
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US6307030B1 (en) 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
JPH0219363A (ja) 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd イミダゾリジン誘導体
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE3835168A1 (de) 1988-10-15 1990-04-19 Bayer Ag N-aryl-stickstoffheterocyclen, mehrere verfahren zu ihrer herstellung und ihre verwendung als herbizide
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
FR2656302B1 (fr) 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
JP2845384B2 (ja) 1991-11-14 1999-01-13 キヤノン株式会社 画像処理装置
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5346913A (en) 1992-05-26 1994-09-13 Rohm And Haas Company N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
DE4316542C1 (de) 1993-05-18 1994-07-21 Schaefer Micomed Gmbh Osteosynthesevorrichtung
FR2715402B1 (fr) 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
AU1687395A (en) 1994-01-21 1995-08-08 Sepracor, Inc. Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US6124211A (en) 1994-06-14 2000-09-26 Fsi International, Inc. Cleaning method
JPH089997A (ja) 1994-06-28 1996-01-16 Shimadzu Corp 核酸合成法およびそれに用いる試薬キット
EP0721944B1 (en) 1994-07-29 2001-01-17 Suntory Limited Imidazolidine derivative and use thereof
FR2725206B1 (fr) 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
DE19540027A1 (de) 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
FR2741346B1 (fr) 1995-11-16 1997-12-19 Roussel Uclaf Nouveau procede de preparation de derives phenylimidazolidine
FR2741342B1 (fr) 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
US5554607A (en) 1995-11-28 1996-09-10 American Home Products Corporation Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis
TW418195B (en) 1995-11-28 2001-01-11 American Home Prod 2-thioxo-imidazolidin-4-one derivatives
CA2238812A1 (en) 1995-11-28 1997-06-05 Theodore Sylvester Sulkowski 2-(substituted sulfanyl)-3,5-dihydro-imidazol-4-one derivatives
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
FR2742749B1 (fr) 1995-12-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques
US6489163B1 (en) 1996-05-08 2002-12-03 Board Of Regents, The University Of Texas System Ribozyme mediated inactivation of the androgen receptor
JP3697320B2 (ja) 1996-06-20 2005-09-21 株式会社日立製作所 光ファイバセンサ
EP1007080B1 (en) 1996-08-30 2007-04-18 Peptech Limited Formulation for the sustained release of peptide agonists and analogues of GnRH
US5726061A (en) 1996-10-08 1998-03-10 Smithkline Beechum Corporation Method of diagnosing and monitoring colorectal cancer
US7053263B2 (en) 1996-10-15 2006-05-30 The Regents Of The University Of California Mouse models of human prostate cancer progression
CA2278851C (en) 1997-02-03 2009-04-07 Dow Agrosciences Llc 2-methoxyimino-2-(pyridinyloxymethyl)phenyl acetamides with carboxylic acid derivatives on the pyridine ring
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6506607B1 (en) 1997-12-24 2003-01-14 Millennium Pharmaceuticals, Inc. Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer
AU4562799A (en) 1998-06-15 2000-01-05 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CN1129581C (zh) 1998-09-22 2003-12-03 山之内制药株式会社 氰基苯基衍生物
DE59905623D1 (de) 1998-09-22 2003-06-26 Degussa Verfahren zur Herstellung von Imidazolidin-2,4-dionen
AU1308400A (en) 1998-10-30 2000-05-22 G.D. Searle & Co. Novel amino acid heterocyclic amide derivatives useful as nitric oxide synthase inhibitors
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
AU2847200A (en) 1999-01-27 2000-08-18 G.D. Searle & Co. Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors
US6350763B1 (en) 1999-07-21 2002-02-26 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammation disease
US6479063B2 (en) 1999-12-27 2002-11-12 Kenneth Weisman Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
CN1209358C (zh) 2000-05-31 2005-07-06 田边制药株式会社 αLβ2介导细胞粘连的抑制剂
EP1302471B1 (en) 2000-05-31 2006-12-27 Mitsui Chemicals, Inc. Sulfur compound and use thereof
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2002053155A1 (en) 2000-12-30 2002-07-11 Geron Corporation Telomerase inhibitor
FR2823209B1 (fr) 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
US6710037B2 (en) 2001-05-01 2004-03-23 Schering Corporation Method of treating androgen-dependent disorders
NZ531870A (en) 2001-10-01 2005-08-26 Bristol Myers Squibb Co Spiro-hydantoin compounds useful as anti-inflammatory agents
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
GB0200283D0 (en) 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds
DE10218963A1 (de) 2002-04-27 2003-11-20 Aventis Pharma Gmbh Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
AU2003262717A1 (en) 2002-08-15 2004-03-03 Genzyme Corporation Brain endothelial cell expression patterns
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
FR2845385B1 (fr) 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR2845384B1 (fr) 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
AU2003284005B2 (en) 2002-10-03 2009-12-17 Forest Laboratories Holdings Limited Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
CA2500977A1 (en) 2002-10-04 2004-04-15 Laboratoires Fournier S.A. 2-thiohydantoine derivative compounds and use thereof in therapeutics
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2004252175A (ja) 2003-02-20 2004-09-09 Kyocera Mita Corp 現像装置、画像形成装置および現像剤の回収方法
PL1632477T3 (pl) 2003-06-12 2017-07-31 Astellas Pharma Inc. Pochodna benzamidu lub jej sól
RU2337908C2 (ru) 2003-06-12 2008-11-10 Ново Нордиск А/С Пиридинилкарбаматы в качестве ингибиторов гормон-чувствительной липазы
US7271188B2 (en) 2003-06-12 2007-09-18 Chugai Seikayu Kabushiki Kaisha Imidazolidine derivatives
TW200523252A (en) 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
EP1709152A4 (en) 2003-12-15 2007-11-07 Univ California MOLECULAR SIGNATURE OF PTEN TUMOR SUPPRESSOR
AU2004305075A1 (en) 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
US7718684B2 (en) 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
EP1732543B1 (en) 2004-03-15 2017-05-10 PTC Therapeutics, Inc. Tetracyclic carboline deratives for inhibiting angiogenesis
EP1621536A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621539A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
JP4912148B2 (ja) 2004-08-03 2012-04-11 中外製薬株式会社 新規イミダゾリジン誘導体
EP1790640A4 (en) 2004-09-09 2009-07-29 Chugai Pharmaceutical Co Ltd NEW IMIDAZOLIDINE DERIVATIVE AND APPLICATION THEREOF
WO2006027266A1 (en) 2004-09-10 2006-03-16 Nitec Pharma Ag Tablets with site time-controlled gastrointestinal release of active ingredient
KR20070108259A (ko) 2005-03-23 2007-11-08 화이자 프로덕츠 인크. Ｃｔｌａ-4 항체와 호르몬 요법에 의한 전립선암의 치료법
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
ES2378778T5 (es) 2005-05-13 2015-09-25 The Regents Of The University Of California Compuesto de diarilhidantoína
FR2889189A1 (fr) 2005-07-28 2007-02-02 Cerep Sa Composes derives d'hydantoine et leur utilistion en tant qu'antagonistes de mchr-1
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CN101032486B (zh) 2006-03-08 2011-05-11 张宏 逆转唑类药物抗真菌活性多药耐药性的药用植物增效剂
CN101032483B (zh) 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
PT3412290T (pt) 2006-03-27 2021-04-19 Univ California Modulador do recetor de androgénios para o tratamento de cancro da próstata e doenças associadas ao recetor de androgénios
EP3020706A1 (en) 2006-03-29 2016-05-18 The Regents Of The University Of California Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
KR20180003636A (ko) 2006-08-25 2018-01-09 코우가 바이오테크놀로지, 인크. 암을 치료하기 위한 방법 및 조성물
CA2838089A1 (en) 2006-08-25 2008-02-28 Cougar Biotechnology, Inc. Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
EP1905439A1 (en) 2006-09-24 2008-04-02 GPC Biotech AG Second line treatment of metastatic hormone refractory prostate cancer using satraplatin
JP4993996B2 (ja) 2006-10-20 2012-08-08 フクダ電子株式会社 輸液ポンプモニタリング装置
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
EP2620432A3 (en) 2007-10-26 2013-12-18 The Regents Of the University of California Diarylhydantoin compounds
MX2010005119A (es) 2007-11-09 2010-05-27 Novartis Ag Corticosteroides para tratar la diarrea inducida por la epotilona o los derivados de epotilona.
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
US20140187641A1 (en) * 2012-08-23 2014-07-03 Gtx Estrogen receptor ligands and methods of use thereof
MX2011008858A (es) 2009-02-24 2012-01-27 Medivation Prostate Therapeutics Inc Compuestos de diarilhidantoina y diariltiohidantoina especificos.
CN102413831B (zh) * 2009-04-29 2014-06-04 拜耳知识产权有限责任公司 取代的咪唑并喹喔啉
WO2011103202A2 (en) 2010-02-16 2011-08-25 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
PT2538785T (pt) 2010-02-24 2018-05-09 Medivation Prostate Therapeutics Llc Processos para a síntese de compostos de diariltiohidantoína e diarilhidantoína
CA2807149C (en) 2010-08-04 2017-05-02 Pellficure Pharmaceuticals, Inc. Novel treatment of prostate carcinoma
US20130253035A1 (en) * 2010-08-16 2013-09-26 Duke University Camkk-beta as a target for treating cancer
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2012142208A1 (en) 2011-04-13 2012-10-18 The Trustees Of The University Of Pennsylvania Bifunctional akr1c3 inhibitors/androgen receptor modulators and methods of use thereof
WO2012145330A1 (en) 2011-04-18 2012-10-26 The University Of British Columbia Fluorene-9-bisphenol compounds and methods for their use
JP2014513730A (ja) * 2011-05-17 2014-06-05 武田薬品工業株式会社 癌を治療するための薬学的組成物および方法
KR101923250B1 (ko) 2011-07-29 2018-11-28 메디베이션 프로스테이트 테라퓨틱스 엘엘씨 유방암의 치료
US20130045204A1 (en) * 2011-08-19 2013-02-21 The University Of British Columbia Fluorinated bisphenol ether compounds and methods for their use
US20130079241A1 (en) * 2011-09-15 2013-03-28 Jianhua Luo Methods for Diagnosing Prostate Cancer and Predicting Prostate Cancer Relapse
JP6309454B2 (ja) * 2011-11-30 2018-04-11 アストラゼネカ アクチボラグ 癌の併用処置
EP3111950B1 (en) 2012-02-24 2021-08-25 The University of Chicago Methods and compositions related to glucocorticoid receptor antagonism and prostate cancer
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
FR2989357B1 (fr) 2012-04-12 2016-02-05 Allia Conditionnement unique pour un ensemble sanitaire comprenant une cuvette de wc suspendu et un bati-support associe
UA115665C2 (uk) 2012-06-07 2017-12-11 Арагон Фармасьютікалз, Інк. Кристалічні форми модулятора андрогенного рецептора
CN109897004A (zh) 2012-09-11 2019-06-18 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
HUE051211T2 (hu) 2012-09-26 2021-03-01 Aragon Pharmaceuticals Inc Antiandrogének nem áttétes, kasztrációrezisztens prosztatarák kezelésére
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EP2872123B1 (en) 2013-04-23 2017-01-04 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
CA2932106A1 (en) 2013-12-06 2015-06-11 F. Hoffmann-La Roche Ag Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
AU2015358497B2 (en) 2014-12-05 2021-04-29 Aragon Pharmaceuticals, Inc. Anticancer compositions
MA41107A (fr) 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
HUE051888T2 (hu) 2014-12-05 2021-03-29 Aragon Pharmaceuticals Inc Rákellenes készítmények
CN104857157A (zh) 2015-05-12 2015-08-26 四川金堂海纳生物医药技术研究所 一种治疗子宫内膜增殖症的汤剂药物及制备方法
EP4438126A2 (en) 2017-10-16 2024-10-02 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Also Published As

Publication number Publication date
CR20150140A (es) 2015-06-11
CY1123716T1 (el) 2022-03-24
CN109999036A (zh) 2019-07-12
HRP20201721T1 (hr) 2021-02-19
US10052314B2 (en) 2018-08-21
HUE051211T2 (hu) 2021-03-01
ZA201808499B (en) 2022-12-21
KR102210825B1 (ko) 2021-02-01
SG10201912719TA (en) 2020-02-27
NZ744456A (en) 2019-09-27
EP2900224A1 (en) 2015-08-05
AU2018206695A1 (en) 2018-08-02
EP3777845A1 (en) 2021-02-17
PH12018502569A1 (en) 2020-12-07
AU2018206695B2 (en) 2020-07-02
ECSP15011764A (es) 2016-01-29
IL237692A0 (en) 2015-05-31
IL304337A (en) 2023-09-01
JP7198310B2 (ja) 2022-12-28
CN104661658A (zh) 2015-05-27
EP3305285B1 (en) 2020-09-02
MY180834A (en) 2020-12-10
JP6527621B2 (ja) 2019-06-05
AU2024204555A1 (en) 2024-07-18
AU2013323861C1 (en) 2024-05-02
JP2019163288A (ja) 2019-09-26
UA117663C2 (uk) 2018-09-10
PT3305285T (pt) 2020-11-24
CN109908114A (zh) 2019-06-21
AU2020244431A1 (en) 2020-10-29
HK1252867A1 (zh) 2019-06-06
US10799489B2 (en) 2020-10-13
IL237692B1 (en) 2023-08-01
SG11201501870RA (en) 2015-04-29
CA2885415C (en) 2021-06-29
KR20220025231A (ko) 2022-03-03
EA201890598A3 (ru) 2019-03-29
WO2014052237A1 (en) 2014-04-03
US10799488B2 (en) 2020-10-13
IN2015DN02387A (es) 2015-09-04
US20140088129A1 (en) 2014-03-27
NZ705815A (en) 2018-08-31
EP3305285A1 (en) 2018-04-11
NI201500042A (es) 2015-09-02
LT3305285T (lt) 2020-12-10
PH12015500615B1 (en) 2015-05-11
USRE49353E1 (en) 2023-01-03
IL312316A (en) 2024-06-01
UA124967C2 (uk) 2021-12-22
BR112015006705A8 (pt) 2019-08-27
US20190269668A1 (en) 2019-09-05
EA030128B1 (ru) 2018-06-29
MX2019010098A (es) 2019-10-15
EA202190820A1 (ru) 2021-10-29
JP6351597B2 (ja) 2018-07-04
EA037806B1 (ru) 2021-05-24
PE20150765A1 (es) 2015-05-15
US20190269667A1 (en) 2019-09-05
NZ745682A (en) 2019-09-27
MX2015003909A (es) 2016-01-08
JP2018150365A (ja) 2018-09-27
DK3305285T3 (da) 2020-10-26
IL237692B2 (en) 2024-07-01
KR20150070192A (ko) 2015-06-24
AU2013323861B2 (en) 2018-04-19
BR112015006705A2 (pt) 2017-07-04
JP6896016B2 (ja) 2021-06-30
MX371020B (es) 2020-01-13
AU2018206695C1 (en) 2020-10-22
CA2885415A1 (en) 2014-04-03
RS60976B1 (sr) 2020-11-30
EA201890598A2 (ru) 2018-07-31
ES2836424T3 (es) 2021-06-25
SI3305285T1 (sl) 2021-03-31
CN115737643A (zh) 2023-03-07
EA201590650A1 (ru) 2015-07-30
US20210000812A1 (en) 2021-01-07
US20180110764A1 (en) 2018-04-26
GT201500071A (es) 2015-12-31
AU2013323861A1 (en) 2015-04-02
JP2015531373A (ja) 2015-11-02
PH12015500615A1 (en) 2015-05-11
US10849888B2 (en) 2020-12-01
KR20210013342A (ko) 2021-02-03
US9884054B2 (en) 2018-02-06
US20180318277A1 (en) 2018-11-08
SG10201902568YA (en) 2019-04-29
PH12018502570A1 (en) 2020-12-07
JP2021130718A (ja) 2021-09-09
HK1212221A1 (en) 2016-06-10

Similar Documents

Publication Publication Date Title
CL2015000715A1 (es) Anti-androgenos para el tratamiento de cáncer prostatico no metastasico y resistente de castracion
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
MX2016007801A (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
EA201490944A1 (ru) Двойной ингибитор met и vegf для лечения рака
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
NI201500151A (es) Terapia de combinación que comprende un compuesto de dihidropirazino-pirazina y un antagonista de receptor de andrógenos para tratar cáncer de próstata.
ECSP14011792A (es) Inhibidores de iap
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
PH12015500867B1 (en) Treatment of prostate cancer with tor kinase inhibitors
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
CO7121349A2 (es) Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek
PH12018502571A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
EA201990411A1 (ru) Способы лечения рака предстательной железы